The Petersburg Post

Thursday, Apr 16th, 2026 - Influential analysis has concluded that "breakthrough" Alzheimer's drugs are unlikely to benefit patients. Researchers said the impact was "well below" what was needed to make a difference to dementia patients' lives. However, their report has also provoked a vicious backlash from equally esteemed scientists who label it as fundamentally flawed. The drugs have been licensed around the world. But the NHS in the UK ...